Icon (ICLR) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Ann Hynes reiterated a Buy rating on Icon (ICLRResearch Report) on July 31 and set a price target of $272.00. The company’s shares closed last Tuesday at $229.07.

According to, Hynes is a 5-star analyst with an average return of 9.7% and a 61.9% success rate. Hynes covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Quest Diagnostics, and Molina Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Icon with a $276.13 average price target, a 17.0% upside from current levels. In a report issued on July 28, J.P. Morgan also maintained a Buy rating on the stock with a $295.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Icon’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.94 billion and net profit of $116 million. In comparison, last year the company earned revenue of $871 million and had a net profit of $73.87 million.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Read More on ICLR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More